Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lars Rejnmark

Showing results (1-10 of 264) with videos related to

Pageof 27
Sort By:
Current Drug Safety|August 12, 2008
Bone effects of glitazones and other anti-diabetic drugsLars Rejnmark
Expert Opinion on Biological Therapy|May 8, 2013
Recombinant hormones in osteoporosisLars Rejnmark
Endocrinology and Metabolism (Seoul, Korea)|April 4, 2024
Treatment of Hypoparathyroidism by Re-Establishing the Effects of Parathyroid HormoneLars Rejnmark
Therapeutic Advances in Chronic Disease|December 20, 2012
Effects of vitamin d on muscle function and performance: a review of evidence from randomized controlled trialsLars Rejnmark
Nature Reviews. Endocrinology|February 6, 2013
The ageing endocrine system: Fracture risk after initiation of antihypertensive therapyLars Rejnmark
Endocrine|November 29, 2017
Quality of life in hypoparathyroidismLars Rejnmark
Current Drug Safety|August 12, 2008
Cardiovascular drugs and boneLars Rejnmark
Current Drug Safety|April 29, 2011
New and emerging antiresorptive treatments in osteoporosisLars Rejnmark, Leif Mosekilde
Clinical Endocrinology|November 10, 2021
The acute effects of milk intake on calcium homeostasis and cardiovascular outcome: A randomized crossover trial in postmenopausal womenRasmus Espersen, Lars Rejnmark
Current Osteoporosis Reports|August 4, 2023
Fracture Risk in Patients with HypoparathyroidismLars Rejnmark, Line Underbjerg
Pageof 27

Showing results (1-10 of 264) with videos related to

Sort By:
Pageof 27
Current Drug Safety|August 12, 2008
Bone effects of glitazones and other anti-diabetic drugsLars Rejnmark
Expert Opinion on Biological Therapy|May 8, 2013
Recombinant hormones in osteoporosisLars Rejnmark
Endocrinology and Metabolism (Seoul, Korea)|April 4, 2024
Treatment of Hypoparathyroidism by Re-Establishing the Effects of Parathyroid HormoneLars Rejnmark
Therapeutic Advances in Chronic Disease|December 20, 2012
Effects of vitamin d on muscle function and performance: a review of evidence from randomized controlled trialsLars Rejnmark
Nature Reviews. Endocrinology|February 6, 2013
The ageing endocrine system: Fracture risk after initiation of antihypertensive therapyLars Rejnmark
Endocrine|November 29, 2017
Quality of life in hypoparathyroidismLars Rejnmark
Current Drug Safety|August 12, 2008
Cardiovascular drugs and boneLars Rejnmark
Current Drug Safety|April 29, 2011
New and emerging antiresorptive treatments in osteoporosisLars Rejnmark, Leif Mosekilde
Clinical Endocrinology|November 10, 2021
The acute effects of milk intake on calcium homeostasis and cardiovascular outcome: A randomized crossover trial in postmenopausal womenRasmus Espersen, Lars Rejnmark
Current Osteoporosis Reports|August 4, 2023
Fracture Risk in Patients with HypoparathyroidismLars Rejnmark, Line Underbjerg
Pageof 27